statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Advances in Clinical Trials and Strategic Collaboration Mark Year's AchievementsRelated Stocks: GLUE...

Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Monte Rosa Therapeutics announces anticipated upcoming milestones

Monte Rosa Therapeutics expects cash to fund operations into 1H26

Monte Rosa Therapeutics reports Q4 EPS (58c), consensus (33c)

MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose...

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics: Q4 Earnings Insights

MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1 and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially...

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1  Pathway Inhibitor

For the last three days, A.I.dvisor has detected that GLUE's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Monte Rosa Therapeutics (GLUE, $5.96) Aroon Indicator entered a Downtrend on February 16, 2024.

Monte Rosa Therapeutics (GLUE, $5.53) Aroon Indicator entered a Downtrend on February 15, 2024.

Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.

 Latest Ratings for...

Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Volume	87,737.00
52-Wk High	$8.84
52-Wk Low	$2.44

GLUE Monte Rosa Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals